Viviphi and Avera Health Confirm Clinical Validation and System-Wide Implementation of the PrecisionPlan Cognitive Computing Platform
Avera Health has announced its plans to implement a new cognitive computing platform system wide. The platform, called PrecisionPlan, was developed in collaboration with Denver-based Viviphi Ltd. PrecisionPlan is designed to generate patient-specific treatment plans in seconds. The artificial intelligence solution utilizes diagnostic, surgical, demographic and other patient-specific information from the electronic medical record system (EMR) and from next-generation tumor sequencing reference laboratories to generate personalized treatment plans and offer clinical guidance in precision medicine.
The strategic collaboration between Avera and Viviphi was established in 2016 to combine Avera’s clinical rules in genomic-based precision medicine with Viviphi’s state-of-the-art cognitive computing platform in oncology. Fred Ashbury, PhD, Chief Scientific Officer of Viviphi noted that genomic science has opened up a whole new way to think about treating cancers, using targeted therapies and immunotherapies designed to attack the actual drivers of cancer.
“These innovative therapies are now significantly improving the odds of survival for many cancer patients who were otherwise compelled to receive multiple lines of treatment using standard of care with substantially greater cost, decreasing chances of success with each line of therapy, increased side effects and poorer quality of life.” Avera is one of a handful of world leaders generating evidence-based knowledge through their practical application of genomic-based precision medicine for cancer patients.
The platform was validated in clinic and through the Avera Molecular Tumor Board in February through April. Implementation and training to start using it system-wide will happen later this year. Avera will be the first health system in the world to run patient data through the Viviphi PrecisionPlan platform. Some other leading NCI Cancer Centers in the US have also signed contracts with Viviphi and preparing to implement the platform in their oncology networks.
Precision oncology offers personalized cancer therapies to patients, based on their individual genomic profile. It has been demonstrated that oncology practices that embrace both the best of genomic science and existing nationally-accepted standards of care achieve better outcomes.
The absence, however, of codified clinical rules in precision medicine in oncology has left many clinicians without practical support and access to the latest knowledge and experts in this dynamic and rapidly evolving field of practice.
These new diagnostic and treatment interventions come at a considerable cost, and health insurers, hospital leaders, and government payers are requiring that local practicing clinicians demonstrate competence in molecular oncology before ordering expensive next-generation tumor sequencing tests and prescribing many of the new and highly effective targeted therapies, combination treatments, and immunotherapies.
Avera is an active member of the recognized Worldwide Innovative Networking (WIN) Consortium in personalized medicine, which is committed to rapidly translating genomic tailored discoveries into standards of care worldwide. Dr. Brian Leyland-Jones, along with his team, has established a next-generation tumor sequencing laboratory.
Gerry Hogue, President and CEO of Viviphi Ltd, highlighted key differentiators of the Viviphi platform. “The Viviphi solution quite literally puts a virtual peer-to-peer consult in the hands of busy oncologists. These professionals want to make the right decisions for patients, not organize and collate data. Oncologists are able to accelerate decision-making, improve clinical through-put and efficiency, make better and more appropriate decisions at the individual patient level, and generate considerable savings for the Centers for Medicare & Medicaid Services (CMS) and other payers, while increasing revenue for their clinic or health care institution.”
Hogue pointed out that the Viviphi PrecisionPlan platform is also completely embeddable within the health institution’s electronic medical record solution, should the provider organization choose to implement in this manner.